Mitsubishi Tanabe Pharma Launches Albumin Injection
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma announced May 19 that it had initiated sales of Medway Injections, recombinant human serum albumin preparations that are jointly developed with Bipha Corp, a MTP subsidiary. Currently, albumin preparations are derived from human plasma. The new products use pichia pastoris as a host and utilize gene recombination technology to reduce contamination by infectious materials in the production process and to enable mass production. Bipha is the manufacturer and Benesis Corp, another MTP subsidiary will co-promote the products. Genetically modified albumin products are approved in the U.S. and Europe as additives to vaccines. (Click here for more - Japanese language)